

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or a solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “U.S. Securities Act”). No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, management, as well as financial statements. The Company does not intend to make any public offering of securities in the United States.*



## **Health and Happiness (H&H) International Holdings Limited**

**健合 (H&H) 國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1112)**

### **PARTIAL REDEMPTION OF SENIOR NOTES**

#### **7.25% SENIOR NOTES DUE 2021**

(ISIN (144A/Reg S): US090688AA08/USG11259AB79)

Common Code (144A/Reg S): 143308804/143308740

CUSIP (144A/Reg S): 090688 AA0/G11259 AB7)

In order to reduce financing cost and optimize capital structure, the board of directors of Health and Happiness (H&H) International Holdings Limited (健合(H&H)國際控股有限公司) (the “**Company**”) resolved after due consideration to redeem, in part, its 7.25% Senior Notes due 2021, of which US\$425 million is outstanding (the “**Notes**”).

The Company is pleased to announce that notification has been sent to the relevant note trustee under the Indenture (as defined below) on October 24, 2019.

Pursuant to the terms of the indenture dated as of June 21, 2016 (as amended or supplemented from time to time, the “**Indenture**”), by and among Biostime International Holdings Limited (currently known as, Health and Happiness (H&H) International Holdings Limited), the entities listed on schedule I thereto, HSBC Bank USA, National Association, as Trustee and The Hongkong and Shanghai Banking Corporation Limited, as Security Agent, the Company has informed the Trustee that US\$300 million in principal amount of the Notes (the “**Redemption Principal Amount**”), representing approximately 70.59% of the outstanding principal amount of the Notes, will be redeemed on November 23, 2019 (the “**Redemption Date**”) at a redemption price equal to 101.8125% of the Redemption Principal Amount, plus accrued and unpaid interest to (but not including) the Redemption Date.

The Company intends to fund the redemption with net proceeds from the issue of US\$300 million 5.625% Senior Notes due 2024 which settled on October 24, 2019 (the “**New Notes**”) and other sources of liquidity available to the Company.

The Company will continue to explore opportunities to reduce the finance cost of the Company and optimize its capital structure.

By order of the board  
**Health and Happiness (H&H) International Holdings Limited**  
**Mr. Luo Fei**  
*Chairman*

Hong Kong, October 24, 2019

*As at the date of this announcement, the executive Directors are Mr. Luo Fei, Mrs. Laetitia Marie Edmee Jehanne ALBERTINI ep. GARNIER and Mr. Wang Yidong; the non-executive Directors are Dr. Zhang Wenhui and Mr. Luo Yun; and the independent non-executive Directors are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.*